Sarepta Therapeutics’ (SRPT) Equal Weight Rating Reaffirmed at Morgan Stanley

Morgan Stanley reissued their equal weight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Monday, Marketbeat.com reports.

Several other research firms have also recently weighed in on SRPT. Oppenheimer dropped their price objective on shares of Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Guggenheim lowered their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, May 8th. Royal Bank of Canada lowered their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating for the company in a research report on Wednesday, May 7th. Finally, Piper Sandler cut shares of Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $70.00 to $36.00 in a research report on Monday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.35.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $20.94 on Monday. Sarepta Therapeutics has a 1 year low of $18.30 and a 1 year high of $173.25. The firm has a 50 day moving average of $45.69 and a 200-day moving average of $85.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $2.06 billion, a P/E ratio of 16.75 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter last year, the firm posted $0.73 EPS. The business’s revenue was up 80.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently modified their holdings of the business. Manchester Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the last quarter. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $30,000. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth about $31,000. Ancora Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after buying an additional 194 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.